Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) is one of the most promising stocks under $100 to buy. On March 16, Rhythm Pharmaceuticals announced topline results from its global Phase 3 EMANATE trial, which evaluated the efficacy of setmelanotide across 4 substudies of rare, genetically driven obesity. The trial did not meet its pre-specified primary endpoints, which measured the difference in mean percent change in BMI (body mass index) compared to a placebo over 52 weeks.

While the primary analysis did not reach statistical significance, post hoc evaluations revealed more encouraging signals in specific patient groups. Significant BMI reductions were observed in patients with heterozygous variants of the POMC/PCSK1 and SRC1 (NCOA1) genes who completed the full 52-week treatment period. These results suggest that while the broader study goals were not met, there is a clear clinical impact for certain genetic profiles, which the company intends to use to inform the development of its next-generation MC4R agonists.

The safety profile of setmelanotide in the EMANATE trial remained consistent with previous clinical experience, with no new safety signals reported. Common side effects included skin hyperpigmentation, nausea, and injection site reactions. Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) now plans to use the data from this trial to refine its approach to treating rare neuroendocrine diseases, focusing on its newer drug candidates and exploring additional gene families identified in earlier exploratory research.

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) is a healthcare company that focuses on rare neuroendocrine diseases. The company’s lead product candidate is IMCIVREE (setmelanotide).

While we acknowledge the potential of RYTM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.